Keytruda combo set to become “standard of care” in kidney cancerAnalysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care Share XKeytruda combo set to become “standard of care” in kidney cancerhttps://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/
Keytruda cuts risk of death by 31% in esophageal cancer trialMSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma Share XKeytruda cuts risk of death by 31% in esophageal cancer trialhttps://pharmaphorum.com/news/keytruda-cuts-risk-of-death-by-31-in-esophageal-cancer-trial/
Merck bags adjuvant okay for Keytruda in melanomaCheckpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval Share XMerck bags adjuvant okay for Keytruda in melanomahttps://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/
Merck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKMerck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in Share XMerck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/merck-cancer-blockbuster-keytruda-funds-rare-disease/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
Keytruda approved for combination lung cancer therapyThe US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line Share XKeytruda approved for combination lung cancer therapyhttps://pharmaphorum.com/news/keytruda-approved-for-combination-lung-cancer-therapy/
Merck & Co’s Keytruda shows potential in head and neck cancer useMerck & Co might be able to find another use for its immunotherapy Keytruda in first line head Share XMerck & Co’s Keytruda shows potential in head and neck cancer usehttps://pharmaphorum.com/news/keytruda-shows-promise-first-line-skin-cancer-treatment/
FDA approves Keytruda in cervical cancerMerck & Co’s blockbuster Keytruda has been approved in advanced second line cervical cancer, becoming the first drug Share XFDA approves Keytruda in cervical cancerhttps://pharmaphorum.com/news/fda-approves-keytruda-cervical-cancer/
ASCO 2018 Preview – what to expect from this year’s conferencepharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the Share XASCO 2018 Preview – what to expect from this year’s conferencehttps://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/
